Thompson Siegel & Walmsley LLC Sells 75,498 Shares of IQVIA Holdings Inc. $IQV

Thompson Siegel & Walmsley LLC lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 27.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 203,496 shares of the medical research company’s stock after selling 75,498 shares during the quarter. Thompson Siegel & Walmsley LLC owned about 0.12% of IQVIA worth $45,870,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. increased its position in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter valued at approximately $27,000. Westside Investment Management Inc. lifted its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Down 0.1%

Shares of NYSE IQV opened at $182.03 on Monday. The stock has a 50-day moving average price of $170.34 and a two-hundred day moving average price of $196.05. IQVIA Holdings Inc. has a 12 month low of $136.41 and a 12 month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market cap of $30.38 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.74 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the company earned $2.70 EPS. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on IQV shares. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research note on Thursday, May 7th. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.